Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $95.25 Average Price Target from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received an average recommendation of "Buy" from the eleven research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $95.25.

JANX has been the subject of a number of analyst reports. Scotiabank cut their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reissued an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 29.40% of the company's stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of JANX. Russell Investments Group Ltd. boosted its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB lifted its stake in shares of Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after buying an additional 444 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after buying an additional 471 shares during the period. Rhumbline Advisers grew its stake in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after buying an additional 599 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Janux Therapeutics by 20.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock valued at $109,000 after buying an additional 686 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Up 2.1%

Shares of JANX traded up $0.47 during trading hours on Friday, reaching $23.35. The stock had a trading volume of 470,560 shares, compared to its average volume of 864,637. The firm has a 50-day simple moving average of $26.55 and a 200 day simple moving average of $35.48. Janux Therapeutics has a 12 month low of $22.48 and a 12 month high of $71.71. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -17.17 and a beta of 2.97.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 9.29%. On average, equities analysts forecast that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.